Recently, results from the OlympiA trial reported improved survival with the use of poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi), olaparib in BRCA1/2 mutation associated early breast cancer patients15. Here, BRCA1 is linked to breast cancer.